Vir Biotechnology Inc (NASDAQ:VIR) shares fell 15% in premarket trade Friday following the company's announcement of a $150 million public stock offering priced at $10 per share.

A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do ...

Many bioentrepreneurs incorrectly estimate the value of their technology by failing to account adequately for the cost, risk, ...

What happened? Shares of Vir Biotechnology fell 18.8% in the afternoon session after the company announced, in a company press release, the pricing of an underwritten public offering of 15 million ...

Shares of Vir Biotechnology fell after the company announced the pricing of its $150 million underwritten public offering. The stock sank 13%, to $10.50, in premarket trading Friday. Through ...

Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising ...

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious ...

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease.

Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR ...

Sana Biotechnology, Inc. reported third-quarter 2026 financial results and business updates, highlighting progress toward clinical studies of its engineered cell therapy programs ...